Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial
- Resource Type
- Article
- Source
- The Lancet HIV; August 2017, Vol. 4 Issue: 8 pe341-e348, 8p
- Subject
- Language
- ISSN
- 24054704; 23523018